T1	Premise 1357 1651	At first follow-up, groups differed only in social functioning, favouring the radiotherapy-only group (mean score 79.0 [SD 3.2] for patients assigned radiotherapy vs 67.4 [2.7] for those assigned radiotherapy and temozolomide; difference between groups 11.6 points [95% CI 3.5-19.7], p=0.0052).
T2	Premise 1652 1730	Over subsequent assessments, HRQOL was much the same between treatment groups.
T3	Claim 1731 1900	Addition of temozolomide during and after radiotherapy for patients with newly diagnosed glioblastoma significantly improved survival without a negative effect on HRQOL.
R1	Support Arg1:T2 Arg2:T3	
R2	Support Arg1:T1 Arg2:T3	
